Production (Stage)
ARS Pharmaceuticals, Inc.
SPRY
$14.98
$0.463.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 275.73M | 314.02M | 204.82M | 218.74M | 223.63M |
| Total Receivables | 10.27M | 9.16M | 1.24M | 542.00K | 618.00K |
| Inventory | 7.27M | 5.21M | 715.00K | -- | -- |
| Prepaid Expenses | 9.63M | 4.67M | 1.29M | 955.00K | 1.15M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 963.00K | 1.23M | 730.00K | 497.00K | 838.00K |
| Total Current Assets | 303.86M | 334.30M | 208.79M | 220.74M | 226.24M |
|
|
|||||
| Total Current Assets | 303.86M | 334.30M | 208.79M | 220.74M | 226.24M |
| Net Property, Plant & Equipment | 1.15M | 1.07M | 935.00K | 782.00K | 814.00K |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 7.49M | 7.69M | 7.88M | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 14.82M | 8.11M | -- | 446.00K | 528.00K |
| Total Assets | 327.32M | 351.15M | 217.60M | 221.97M | 227.58M |
|
|
|||||
| Total Accounts Payable | 8.32M | 14.13M | 8.28M | 3.27M | 839.00K |
| Total Accrued Expenses | 10.33M | 4.15M | 7.04M | 3.07M | 2.44M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 73.00K | 42.00K | 102.00K | 160.00K | 217.00K |
| Total Finance Division Other Current Liabilities | 8.90M | 5.13M | 1.20M | 224.00K | 215.00K |
| Total Other Current Liabilities | 8.90M | 5.13M | 1.20M | 224.00K | 215.00K |
| Total Current Liabilities | 27.62M | 23.44M | 16.62M | 6.73M | 3.72M |
|
|
|||||
| Total Current Liabilities | 27.62M | 23.44M | 16.62M | 6.73M | 3.72M |
| Long-Term Debt | 69.38M | 69.38M | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 1.34M | 1.53M | -- | -- | -- |
| Total Liabilities | 98.34M | 94.36M | 16.62M | 6.73M | 3.72M |
|
|
|||||
| Common Stock & APIC | 386.15M | 379.88M | 373.88M | 369.50M | 365.59M |
| Retained Earnings | -157.25M | -123.31M | -173.24M | -154.11M | -141.60M |
| Treasury Stock & Other | 72.00K | 220.00K | 339.00K | -145.00K | -124.00K |
| Total Common Equity | 228.97M | 256.80M | 200.98M | 215.24M | 223.87M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 228.97M | 256.80M | 200.98M | 215.24M | 223.87M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 228.97M | 256.80M | 200.98M | 215.24M | 223.87M |
|
|
|||||